Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACHN is in the long-term down -83% below S&P in 7 years.
Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
|Shares Outstanding||EPS||-0.47||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-9|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.83%||ROE||-27.14%||ROI|
|Current Ratio||19.64||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||138.96 M||Cash From Investing Activities||-148.58 M||Cash From Operating Activities||-17.32 M||Gross Profit|
|Net Profit||-19.26 M||Operating Profit||-19.4 M||Total Assets||279.42 M||Total Current Assets||255.58 M|
|Total Current Liabilities||13.01 M||Total Debt||610 K||Total Liabilities||13.41 M||Total Revenue|
|High 52 week||5.15||Low 52 week||2.65||Last close||3.1||Last change||1.31%|
|RSI||20.21||Average true range||0.12||Beta||0.8||Volume||2.41 M|
|Simple moving average 20 days||-9.36%||Simple moving average 50 days||-12.63%||Simple moving average 200 days||-13.92%|
|Performance Week||-1.27%||Performance Month||-10.92%||Performance Quart||-26.37%||Performance Half||6.9%|
|Performance Year||-26.01%||Performance Year-to-date||7.64%||Volatility daily||2.03%||Volatility weekly||4.55%|
|Volatility monthly||9.32%||Volatility yearly||32.3%||Relative Volume||236.65%||Average Volume||1.22 M|
|New High||New Low|
2019-09-19 06:19:42 | How Much Cash Is Left In The Bank For Achillion Pharmaceuticals, Inc. NASDAQ:ACHN?
2019-09-07 09:30:01 | Why Is Achillion ACHN Down 11.2% Since Last Earnings Report?
2019-08-29 17:00:00 | Achillion to Present at the Baird 2019 Global Healthcare Conference
2019-08-09 08:24:12 | Achillion ACHN Reports Wider Y/Y Loss in Q2, Revenues Nil
2019-08-08 07:30:00 | Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2019-07-26 17:29:00 | Why Achillion Pharmaceuticals Stock Flew Higher Again Today
2019-07-23 12:30:00 | Why Achillion Pharmaceuticals Stock Is Soaring Again Today
2019-07-22 16:30:00 | Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today
2019-07-22 15:41:50 | Why Achillion Pharmaceuticals Stock Jumped Today
2019-07-17 06:00:00 | Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update
2019-07-10 09:23:57 | Does Achillion Pharmaceuticals, Inc. NASDAQ:ACHN Have A High Beta?
2019-07-04 08:35:12 | Alexion's Ultomiris Receives EU Approval for PNH in Adults
2019-06-28 08:45:12 | Alexion Receives FDA Approval for Label Expansion of Soliris
2019-06-26 18:29:56 | Here’s What Hedge Funds Think About Achillion Pharmaceuticals, Inc. ACHN
2019-06-21 11:05:03 | Alexion's sBLA for Ultomiris Gets Priority Review From FDA
2019-06-13 07:00:00 | Achillion to Present at the JMP Securities Life Sciences Conference
2019-06-08 09:30:01 | Why Is Achillion ACHN Down 1.4% Since Last Earnings Report?
2019-05-14 06:00:00 | Achillion Granted Twentieth Patent for Factor D Portfolio
2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1
2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
2019-05-09 16:00:00 | What You Need to Know About Achillion Pharmaceuticals' Q1 Update
2019-05-09 10:19:41 | Achillion: 1Q Earnings Snapshot
2019-05-09 06:00:00 | Achillion Reports First Quarter 2019 Financial Results
2019-05-02 06:00:00 | Biotech Bets and a Goodbye from a Favorite Expert
2019-04-06 09:30:01 | Why Is Achillion ACHN Up 25.6% Since Last Earnings Report?
2019-04-04 10:23:02 | Achillion Meets Enrollment Target in Kidney Disease Studies
2019-04-03 12:50:00 | Why Achillion Pharmaceuticals Stock Is Jumping Today
2019-04-03 06:00:00 | Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
2019-03-28 16:41:08 | Achillion Completes Enrollment in Rare Blood Disorder Study
2019-03-27 06:00:00 | Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4
2019-03-08 06:00:00 | Achillion to Present at the Barclays Global Healthcare Conference
2019-03-07 06:00:00 | Achillion Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-21 12:57:06 | Why a Connecticut pharma firm moved its C-suite to Blue Bell
2019-02-19 06:00:00 | Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
2019-02-12 07:50:00 | Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2019-02-11 06:00:00 | Achillion Appoints Brian Di Donato as Chief Financial Officer
2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up
2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
2019-01-10 10:49:30 | Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
2019-01-10 05:00:00 | Top Picks 2019- Achillian Pharmaceuticals ACHN
2019-01-03 06:00:00 | Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors